Purinergic Signalling: Therapeutic Developments

Area of Science:

• Biochemistry and Pharmacology
• Molecular Biology
• Physiology

Background:

• Purinergic signaling, the role of nucleotides as extracellular messengers, was conceptualized in 1972.
• Widespread acceptance and research acceleration occurred in the early 1990s following the cloning and characterization of purinergic receptor subtypes.
• Key receptor families include P1 (adenosine) receptors, P2X ion channels, and P2Y G protein-coupled receptors.

Purpose of the Study:

• To review the evolution of purinergic signaling research from fundamental physiology to its current focus on pathophysiology and therapeutic potential.
• To highlight established and emerging therapeutic applications targeting various purinergic receptor subtypes.
• To underscore the broad scope of diseases potentially treatable through modulation of purinergic pathways.

Main Methods:

• Review of historical and recent scientific literature on purinergic signaling.
• Analysis of pharmacological data and clinical trial outcomes for purinergic agents.
• Identification of established and investigational therapeutic targets within the purinergic system.

Main Results:

• Established therapies include P1 receptor agonists for supraventricular tachycardia and P2Y12 antagonists (e.g., clopidogrel) for thrombosis.
• Emerging treatments include P2Y2 agonists for dry eye and P2X3 antagonists in clinical trials for chronic cough, pain, and hypertension.
• Investigational uses for purinergic agents span inflammatory, neurodegenerative, metabolic, and oncological conditions.

Conclusions:

• Purinergic signaling has transitioned into a significant area for therapeutic intervention across a wide spectrum of human diseases.
• Targeting specific purinergic receptors offers promising strategies for managing conditions ranging from cardiovascular and neurological disorders to inflammatory diseases and cancer.
• Continued research into purinergic signaling mechanisms and drug development holds substantial potential for future medical advancements.